Abstract
Ivermectin is a broad spectrum antiparasitic veterinary drug introduced in human medicine in 1987. It is considered the drug of choice in onchocerciasis and strongyloidiasis infections, and remains as a therapeutic option for mass treatment in lymphatic filariasis, for which it has widely proved its efficacy. While research continued for human use, new therapeutic targets for ivermectin have emerged. It is currently the better therapeutic option in the treatment of gnathostomiasis and crusted scabies, and could be an alternative option in ascariasis and Mansonella infections. Although these uses are already included in clinical guidelines, more trials are needed to increase their grade of evidence and to obtain their official approval. Concerning other minor uses such as the treatment of enterobiasis or against Trichuris trichiura, more research is still needed in order to test the real activity of ivermectin. The use of ivermectin in human medicine has shown an outstanding low rate of adverse reactions, with the exception of treatment of loiasis and onchocerciasis, where the death of a high microfilarial load may cause severe encephalopathy. However special attention must be paid to the emergence of the first documented cases of resistance in treatment of scabies.
Keywords: Filariasis, human medicine, ivermectin, onchocerciasis, strongyloidiasis
Current Pharmaceutical Biotechnology
Title:Ivermectin in Human Medicine, An Overview of the Current Status of Its Clinical Applications
Volume: 13 Issue: 6
Author(s): P. Gonzalez, F. A. Gonzalez and K. Ueno
Affiliation:
Keywords: Filariasis, human medicine, ivermectin, onchocerciasis, strongyloidiasis
Abstract: Ivermectin is a broad spectrum antiparasitic veterinary drug introduced in human medicine in 1987. It is considered the drug of choice in onchocerciasis and strongyloidiasis infections, and remains as a therapeutic option for mass treatment in lymphatic filariasis, for which it has widely proved its efficacy. While research continued for human use, new therapeutic targets for ivermectin have emerged. It is currently the better therapeutic option in the treatment of gnathostomiasis and crusted scabies, and could be an alternative option in ascariasis and Mansonella infections. Although these uses are already included in clinical guidelines, more trials are needed to increase their grade of evidence and to obtain their official approval. Concerning other minor uses such as the treatment of enterobiasis or against Trichuris trichiura, more research is still needed in order to test the real activity of ivermectin. The use of ivermectin in human medicine has shown an outstanding low rate of adverse reactions, with the exception of treatment of loiasis and onchocerciasis, where the death of a high microfilarial load may cause severe encephalopathy. However special attention must be paid to the emergence of the first documented cases of resistance in treatment of scabies.
Export Options
About this article
Cite this article as:
Gonzalez P., A. Gonzalez F. and Ueno K., Ivermectin in Human Medicine, An Overview of the Current Status of Its Clinical Applications, Current Pharmaceutical Biotechnology 2012; 13 (6) . https://dx.doi.org/10.2174/138920112800399248
DOI https://dx.doi.org/10.2174/138920112800399248 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice
Current Reviews in Clinical and Experimental Pharmacology Clinical Interpretation of Drug Susceptibility Tests in Tuberculosis
Current Respiratory Medicine Reviews Blood-Brain Barrier Transport of Short Proline-Rich Antimicrobial Peptides
Protein & Peptide Letters Activation of Latent HIV-1 Expression by Protein Kinase C Agonists. A Novel Therapeutic Approach to Eradicate HIV-1 Reservoirs
Current Drug Targets Hallucinations and Delusions in Children and Adolescents
Current Psychiatry Reviews Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Bacteriophages and Phage-Derived Proteins – Application Approaches
Current Medicinal Chemistry Efficient Synthesis and Antibacterial Profile of Bis(2-hydroxynaphthalene- 1,4-dione)
Current Topics in Medicinal Chemistry Melatonin Treatment Enhances Aβ Lymphatic Clearance in a Transgenic Mouse Model of Amyloidosis
Current Alzheimer Research Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry New Drugs and Treatment Regimens
Current Respiratory Medicine Reviews An Update on the Synthesis and Antibacterial Effects of Carbapenems
Recent Patents on Anti-Infective Drug Discovery Polymer-based Nanodevices for Effective Antimicrobial Therapy: Synthetic Strategies and Applications
Current Applied Polymer Science Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Role of Grina/Nmdara1 in the Central Nervous System Diseases
Current Neuropharmacology Multimodalities Imaging of Immunoglobulin 4-related Cardiovascular Disorders
Current Cardiology Reviews Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets